October 4, 2026 — Huntington Beach, California
Lionheart Health, Inc. is advancing an intellectual property portfolio built around a central goal: helping the body maintain healthy function and repair damaged or aging tissues through programmable bioelectric signaling, regenerative biologics and targeted delivery technologies.
An updated working inventory identifies 63 patent and application entries representing approximately 1,137 issued, published or estimated proposed claims across the Leonhardt/Lionheart Health portfolio and the identified licensed or optioned Schuler and Stangl technologies. This inventory excludes circulatory-assist and accelerated orthodontic tooth-movement inventions.
Intellectual Property Portfolio
| Intellectual property portfolio | Patent/application entries | Aggregate claim count |
|---|---|---|
| Leonhardt / Lionheart Health | 50 | 920 |
| Eleanor Schuler — identified licensed and optioned portfolio | 11 | 177 |
| Manfred Stangl — identified Klotho-expressing cell patents | 2 | 40 |
| Combined working inventory | 63 | 1,137 |
The estimate comprises 502 claims in issued patents, 155 claims in separate published applications, and 480 estimated claims across 24 additional announced or prepared applications, using an assumption of 20 claims per application where public claim text was unavailable. Applications and grants arising from the same filing are counted once in this inventory.
At the foundation of Lionheart’s platform is research into electrical signals that influence the production and release of naturally occurring proteins. These include Klotho, follistatin, SDF-1, PDGF, BDNF, GDF10, COL17A1, osteoprotegerin and other proteins associated with cellular maintenance, tissue repair and regeneration. The portfolio also includes applications addressing Sirtuins, Sestrins, NANOG and newer signaling targets.
In everyday terms, these technologies aim to give cells carefully programmed instructions: recruit repair cells, support blood-vessel formation, regulate inflammation, maintain tissue elasticity and encourage regenerative activity. Different signals and combinations are being investigated for different tissues and treatment objectives.
For healthspan longevity, Lionheart is developing approaches focused on preserving muscle performance, brain function, immune resilience and organ health as people age. Recent application announcements expand the research portfolio into FOXO3–AMPK–mTOR pathways, Menin, OSER1, thymulin, osteocalcin and mitochondrial function. These technologies support the company’s broader investigation of coordinated biological processes involved in healthy aging.
For regenerative aesthetics, the portfolio supports research into skin quality, hair regeneration, scalp health, tissue elasticity and recovery following aesthetic procedures. Programs such as SkinStim™ and HairCell™ investigate combinations of bioelectric signaling, light-based treatments and regenerative materials. Newly announced applications include bioelectric hair repigmentation and enhanced regenerative biologics, extending the platform beyond individual stimulation signals toward integrated treatment systems.
For deep organ regeneration, Lionheart’s research combines targeted stimulation with regenerative cells, nutrient hydrogels and controlled delivery. Programs under development address the heart, kidneys, lungs, brain and other organs. Platforms including Lionheart Octopus™, KlothoPatch™ II, CerebraCell™ and RegenaLung™ explore different ways to deliver, sustain and coordinate regenerative support at the intended treatment site.
The three inventor portfolios contribute complementary capabilities. Leonhardt’s inventions address programmable protein expression, tissue treatment and combinations of stimulation with biologics and delivery systems. Schuler’s technologies address recording, processing and applying biological electrical signals, including organ-control and cancer-treatment approaches. The identified Stangl patents address genetically modified mesenchymal stem cells that express Klotho.
Together, these capabilities support Lionheart’s strategy of investigating both the signals that guide tissue function and the biological materials that may help tissues repair. The aim is to develop coordinated approaches tailored to the organ, tissue and patient being studied.
Lionheart Health will continue refining its intellectual property inventory as prepared applications are filed, pending applications progress and new patents issue. The reported total is a working portfolio estimate rather than a legal opinion on ownership, license scope, validity or enforceability. Claims may overlap across patents and jurisdictions, and proposed claims may change.
Estimated combined total: 1,137 claims, using the previously identified 63 patent/application entries and estimating 20 claims each for the 24 additional news-announced applications, including prepared applications.
See Lionheart Longevity NEWS >
Claim Count by Portfolio
| Portfolio | Claims in issued patents | Claims in separate published applications | Estimated claims in new announced/prepared applications | Total claims |
|---|---|---|---|---|
| Leonhardt / Lionheart Health | 285 across 17 patents | 155 across 9 applications | 480 — 24 × 20 | 920 |
| Eleanor Schuler | 177 across 11 patents | — | — | 177 |
| Manfred Stangl — Klotho cells | 40 across 2 patents | — | — | 40 |
| TOTAL | 502 | 155 | 480 estimated | 1,137 |
The calculation uses the numbered claims in the granted or published documents. For example, GDF10 has 4 issued claims, BDNF has 14, and the Stangl U.S. and European grants have 25 and 15, respectively. The Schuler subtotal includes both neurocode-platform grants, each with 11 claims, plus the nine cancer-related grants.
657 documented claims + 480 estimated claims = 1,137 total claims.
This retains your exclusions for circulatory assist and accelerated tooth movement. It counts independent and dependent claims, including overlapping claims across patents and jurisdictions; it is an aggregate portfolio estimate, not 1,137 distinct enforceable rights.
Patent and Application Entries
Including prepared applications in the Leonhardt/Lionheart Health count:
| Portfolio | Issued patents identified | Published applications counted separately | Additional announced applications, including prepared | Total |
|---|---|---|---|---|
| Leonhardt / Lionheart Health | 17 | 9 | 24 | 50 |
| Eleanor Schuler — licensed and optioned portfolio previously identified | 11 | Not separately established | — | 11 |
| Manfred Stangl — licensed genetically modified Klotho-cell technology | 2 | Not separately established | — | 2 |
| TOTAL IDENTIFIED | 30 | 9 | 24 | 63 |
Combined working total: 63 patents, pending and application entries, including prepared announced applications in process of early filing steps. Many other applications are in process as well, un-announced to date, and these are NOT counted. The total with these would exceed 73 patents issued and pending when filings are registered, with more in the works.
This excludes Leonhardt circulatory-assist and accelerated tooth-movement inventions. Stangl’s U.S. and European grants count as two patents within one family. The total is not 63 enforceable patents; additional Schuler or Stangl pending applications could increase it.
Partial List of Leonhardt Patents and Patents Pending for Bioelectric Protein Expressions
1. Protein expression, release or modulation explicitly identified in patent claims
| Patent or published application | Status/document examined | Proteins expressly named in the claims | Claim detail |
|---|---|---|---|
| US10,646,644 — Stimulator, pump and composition | Issued patent | SDF-1/CXCL12; PDGF | Named in claim 1. The description discloses a substantially larger protein program, listed below. Google Patents |
| US10,960,206 — Bioelectric stimulator | Issued patent | SDF-1; IGF-1; EGF; PDGF; eNOS; Activin B; RANKL; HGF | Expression targets in claims 2–5 and 7. Claim 6 separately names additional delivered factors; see the next table. Google Patents |
| US12,109,410 — Bioelectric stimulator | Issued patent | Activin; EGF; Follistatin; HGF; IGF-1; PDGF; RANKL; SDF-1; Tropoelastin; VEGF | Claim 1 expressly enumerates these expression targets; claim 14 also identifies follistatin, tropoelastin and VEGF. Google Patents |
| US11,419,688 — Skin treatment system | Issued patent | SDF-1; PDGF; Tropoelastin; Follistatin; IGF-1 | Named in claim 1’s treatment system. Google Patents |
| US11,878,161 — COL17A1 modulation | Issued patent | COL17A1 / Collagen XVII | Claims include increased expression, production of collagen XVII, and decreased expression. Google Patents |
| US11,471,686 — Klotho modulation | Issued patent | Klotho | Claims concern Klotho expression and/or release. Google Patents |
| US12,226,639 — Klotho modulation | Issued patent | Klotho | Additional issued Klotho expression/modulation claims. Google Patents |
| US11,446,488 — Kidney treatment | Issued patent | Klotho | Claim 1 uses muscle stimulation to increase Klotho for kidney treatment. Google Patents |
| US11,849,910 — Heart valve decalcification, regeneration and repair | Issued patent | Tropoelastin; Klotho | Claim 10 expressly upregulates these proteins. Claim 20 separately administers elastin nanoparticles. Google Patents |
| US11,167,141 — Bioelectric blood pressure management | Issued patent | SDF-1; VEGF; IGF-1; PDGF; Tropoelastin; HGF; EGF; eNOS; Follistatin | First six in claim 1; EGF, eNOS and follistatin in claim 2. Google Patents |
| US11,110,274 — System and method for treating inflammation | Issued patent | IGF-1; TNF-α; CXCL5; IL-1β; TGF-β; IL-10; VEGF; eNOS; SDF | Claims 5, 9, 10 and 12 identify expression/release targets. Claim 9 includes timed increases and inhibition of inflammatory proteins. Google Patents |
| US10,695,563 — Orthodontic treatment | Issued patent | RANKL; TNF-α; SDF-1; VEGF; IGF-1; OPG | Production, increase or release in claims 1, 2, 5, 7 and 9. Google Patents |
| US11,691,007 — Bioelectric OPG treatment of cancer | Issued patent | Osteoprotegerin / OPG | Claim 1 increases OPG. Google Patents |
| US11,433,231 — Bioelectric stimulation for Sonic Hedgehog expression | Issued patent | Sonic Hedgehog / SHH | Explicit SHH expression claims. Google Patents |
| US12,642,967 — BDNF modulation | Issued patent | Brain-derived neurotrophic factor / BDNF | USPTO’s published claim 1 identifies increased BDNF. patentsgazette.uspto.gov |
| US12,611,540 — GDF10 modulation | Issued patent identified; complete grant claims not retrieved | Growth differentiation factor 10 / GDF10 | Grant identity and expression/release subject matter verified; full claim-by-claim extraction remains incomplete. patentsgazette.uspto.gov |
| US20220409894A1 — VEGF/pulse-width modulation | Published application | VEGF; Activin B; BMP9; COL17A1; CXCL5; EGF; Follistatin; HGF; HIF-1α; IGF-1; IL-6; Klotho; OPG; PDGF; RANKL; SDF-1; SHH; TNF; TGF-β1 | VEGF modulation plus the broader protein list in claim 17. Google Patents |
| US20220370791A1 — BMP9 modulation | Published application | BMP9 / GDF2 | Increased and decreased BMP9 expression. Google Patents |
| US20220226643A1 — S100 modulation | Published application | S100; S100A; Klotho; “LIM muscle”; Follistatin; SDF-1; PDGF; EGF; HGF; IGF-1 | S100/S100A expression; additional proteins in claims 9 and 13. “LIM muscle” is the application’s terminology, without a specific gene identifier in those claims. Google Patents |
| US20240285949A1 — Modulation of sestrins | Published application | Sestrin / Sestrins | Claims identify the protein family; they should not be expanded into individually verified claims for every SESN subtype. Google Patents |
| US20240108886A1 — SIRT modulation | Published application | Sirtuins/SIRT; SIRT1; SIRT6 | Family-level claims, with SIRT1 and SIRT6 expressly identified in claims 10–12. Justia Patents Search |
| US20240158813A1 — NANOG modulation | Published application | NANOG | Explicit NANOG expression/modulation claims. Google Patents |
| US20230191128A1 — FABP4 modulation | Published application | FABP4; Klotho; Follistatin | FABP4 modulation/downregulation; Klotho upregulation in claims 5 and 11; follistatin upregulation in claim 7. Google Patents |
| US20260183342A1 — Allogenic implants for inflammatory conditions | Published application; Leonhardt is a named co-inventor | PD-L1 as an expression target; Interferon-γ and G-CSF as administered components | Claim 19 uses interferon-γ to increase PD-L1 expression; claim 20 identifies G-CSF. Lionheart licensing was not verified. Justia Patents Search |
| US11,185,691 — Tumor therapy | Issued patent | Unnamed tumor-surface proteins and unnamed proteins around the tumor | Claims 1, 10 and 18 address protein concentration or surface expression without naming individual proteins. They cannot be converted into a specific protein list. Google Patents |
2. Additional proteins disclosed in patents, including delivered factors
| Additional protein or family | Where found | Treatment in the document |
|---|---|---|
| Activin A; GDF11; Human growth hormone/HGH; HIF-1α; IL-6 | US10,960,206, claim 6 | Separately delivered factors. That claim also names GDF10, SDF-1, IGF-1, Activin B, eNOS, PDGF, HGF and tropoelastin. Google Patents |
| Relaxin; Neurogenin-3/NEUROG3; GDF11; Activin A | US10,646,644 description | Expressly disclosed in bioelectric release/production embodiments. FGF also appears as a composition component. Google Patents |
| IL-6 and other inflammatory factors | US11,110,274, claim 6 | Delivered cocktail includes IL-6, IL-10, IL-1β, TGF-β, TNF-α, IGF-1 and CXCL5. Google Patents |
| Elastin | COL17A1 and heart-valve patents | Administered material; distinguish from inducing expression of its precursor tropoelastin. Google Patents |
| BMP10; IL-1; IL-9; IL-33; Neurogenin-3 | Leonhardt’s published platform inventory | Company identified them as protein expressions under testing/evaluation; a corresponding specific expression claim was not verified for each. Leonhardt Ventures |
3. Newer patent-pending targets and filing announcements
| Filing/platform announcement | Announced status/date | Named protein-expression or signaling targets |
|---|---|---|
| Nrf2 aneurysm platform — AortaCell/CerebraCell | Newly filed provisional; April 16, 2026 | NRF2/NFE2L2, with Klotho, SDF-1, PDGF, VEGF and eNOS. Announcement identifies Lionheart as licensee and describes exclusive distribution rights. lionheartlongevity.com |
| 15-PGDH platform | New patent filing announced; April 2026 | 15-hydroxyprostaglandin dehydrogenase / 15-PGDH / HPGD. Lionheart Longevity |
| FOXO3–AMPK–mTOR platform | Provisional application described as “in process”; May 2026 | FOXO3; AMPK; mTOR. AMPK is a kinase complex; pathway modulation does not establish expression of every subunit. Lionheart Longevity |
| HMGB1 regeneration platform | New provisional announced; May 9, 2026 | HMGB1, with combinations involving Klotho, sestrins, sirtuins, apelin, GDF10, tropoelastin, SDF-1 and PDGF. Lionheart Longevity |
| Wnt regeneration platform | Provisional announced; May 12, 2026; exclusive Lionheart license stated | Wnt signaling, combined with Klotho enhancement. The announcement does not individually enumerate all Wnt ligands. Lionheart Longevity |
| Menin brain platform | Provisional filed; June 1, 2026; exclusive Lionheart rights stated | Menin/MEN1. Related Brain Band targets include Klotho, BDNF, GDF10, SDF-1, sirtuins, sestrins, apelin, eNOS, VEGF and SHH. Lionheart Longevity |
| Osteocalcin platform | New provisional announced; June 4, 2026 | Osteocalcin/BGLAP expression and release. Lionheart Longevity |
| OSER1 longevity platform | Provisional prepared; June 4, 2026; exclusive Lionheart license stated | Oxidative Stress Responsive Serine Rich Protein 1 / OSER1. Lionheart Longevity |
| Accelerated orthodontic movement | Provisional filed; June 2026 | IL-1β, RANKL, VEGF, BMP2, SDF-1, PDGF and eNOS. Intended exclusive licensee: OrthodontiCell, rather than an established Lionheart license in this announcement. PGE2 is also targeted but is not a protein. Lionheart Health Stim |
| CerebraCell multimodal brain platform | Provisional completed, announced July 2026 | Klotho, BDNF, GDF10, GDF11, HMGB1, SDF-1, PDGF, VEGF, eNOS, IGF-1, apelin, sestrins, sirtuins, FOXO3, AMPK, mTOR, Wnt, BMP9, OPG, SHH, HIF-1α, CXCL5, LIM-domain proteins, S100, follistatin, tropoelastin and collagen pathways. lionheartlongevity.com |
| Polylaminin platform | Provisional filed, announced July 2026 | Laminin/polylaminin. Polylaminin is a polymerized laminin preparation; specific laminin chains were not individually disclosed in the announcement. lionhearthealthstim.com |
| Thymulin platform | Provisional prepared; July 2026 | Thymulin, a thymic peptide; combinations include Klotho. Lionheart Longevity |
| OrthoStim/Pentadeca Arginate combination | Provisional filed; July 30, 2026; exclusive Lionheart license stated | Announcement identifies PDA+ combination therapy, but supplies no additional individually named endogenous protein-expression target. Lionheart Longevity |
| Hair repigmentation platform | Provisional filed; August 22, 2026 | Extensive candidate protein list—expanded in the next table. lionheartlongevity.com |
| MitoCell/PCUp | Provisional filed; August 2026 | Klotho, AMPK, sestrins and sirtuins among named pathways. Phosphatidylcholine and choline are not proteins. lionheartlongevity.com |
| Bioelectrically Enhanced Exosomes | Provisional filed; August 26, 2026 | VEGF; SDF-1/CXCR4; BDNF; PI3K/AKT; MAPK among named cargo/signaling pathways. These are not all separately verified expression claims. lionheartlongevity.com |
| Mitochondrial function/muscle/sarcopenia | Patent-application development announced; August 2026 | SYK modulation/inhibition and mitochondrial respiratory-chain supercomplex pathways. Individual respiratory-chain proteins are not completely enumerated. lionheartlongevity.com |
| Glial-cell brain repair | Provisional filed; September 6, 2026 | Named integration targets include BDNF, Klotho and GDF10; the filing also concerns glial-cell biology beyond these proteins. lionheartlongevity.com |
| DentaCell regenerative dentistry | Provisional filed, according to announcement | SDF-1, PDGF, CXCR4, VEGF, eNOS, HIF-1α, BMP9, RUNX2, osteocalcin, alkaline phosphatase, OPG, RANKL, tropoelastin, COL17A1, Klotho, sestrins, sirtuins and apelin; collagen-remodeling pathways also named. lionheartlongevity.com |
| Klotho nanoflowers | Nonprovisional filing announced; December 2025 | Klotho formulation/delivery platform. lionhearthealthstim.com |
| Bioelectric-enhanced peptide uptake | Provisional filed; December 2025 | Named platform proteins include Klotho, sirtuins, sestrins, apelin, LIM, BDNF, SDF-1, PDGF, VEGF and S100A. lionhearthealthstim.com |
| SuperPRF/Klotho | Provisional filing announced; February 2025 | Klotho, PDGF, SDF-1, VEGF, eNOS, follistatin and S100A. leonhardtventures.com |
| KlothoPatch II | Prepared application announced; September 2026 | Klotho. lionheartlongevity.com |
4. Full named candidate list from the hair-repigmentation filing announcement
Source: lionheartlongevity.com
| Target group | Named proteins, receptors or peptides |
|---|---|
| Stem-cell/melanocyte support | SCF/KITLG; c-KIT/KIT; WNT3A; WNT10B; β-catenin |
| Pigment transcription and synthesis | MITF; TYR; TYRP1; DCT/TYRP2 |
| Hormonal/receptor signaling | α-MSH; POMC; MC1R; EDN1; EDNRB |
| Growth and repair | FGF2; FGF7/KGF; VEGF-A; IGF-1; HGF; PDGF-AA; PDGF-BB; EGF |
| Neurotrophic/recruitment | BDNF; NGF; GDNF; CXCL12/SDF-1 |
| Longevity/antioxidant | Klotho; NRF2; catalase; SOD1; SOD2; GPX1 |
| Survival/metabolism | BCL-2; survivin/BIRC5; FOXO3; SIRT1; PGC-1α |
| Follicular/developmental balance | TGF-β; BMP pathways; Noggin; SHH; Follistatin |
| Inflammation | IL-10, with reduction of TNF-α, IL-6 and IL-17 signaling |
5. Additional new targets mentioned in news, without a separately verified new filing
| News program | Additional targets | Evidence distinction |
|---|---|---|
| Cardiac regeneration expansion, August 2026 | TBX20; PITX2/PITX2c; MEIS1; NPPA/pro-ANP/ANP, with VEGF and Klotho | Research announcement. MEIS1 is proposed for reduction/modulation, while NPPA/pro-ANP is proposed for increased expression. lionheartlongevity.com |
| LiverCell macrophage program, September 2026 | Sestrin-2/SESN2; SIRT1; SIRT3; SIRT6; Klotho | Explicit proposed research targets. NF-κB, NLRP3 and TGF-β also appear as mechanistic pathways in the discussion; this does not establish separate new claims to them. lionheartlongevity.com |
| Multi-protein regeneration platform | Collagen I; Collagen III; FGF2; BMP2 | Expressly named company research pathways, alongside previously listed targets. Separate expression claims were not verified from this article. |
Klotho Foundation Used Throughout the Table
Issued: U.S. 11,471,686 and 12,226,639 — Klotho Modulation. patents.google.com
Patent pending, as described in company announcements: Klotho-expressing stem cells in nutrient hydrogel; bioelectric-enhanced Klotho-expressing cells; Klotho Nanoflowers™; Super PRF™ + Klotho-expressing cells; Lionheart Octopus™. KlothoPatch™ II was announced as a prepared provisional application, so filing remains to be confirmed. lionheartlongevity.com
Technology Platforms and Proposed Applications by Function
The table maps relevant technology platforms and proposed applications.
| Function | Issued patents identified | Patent-pending technologies / new applications |
|---|---|---|
| Muscle Health | Klotho Modulation — 11,471,686; 12,226,639; Bioelectric Stimulator — 12,109,410; Stimulator, Pump and Composition — 10,646,644 | Klotho-related pending platforms listed above; mitochondrial function/muscle strength/sarcopenia application; MitoCell™/PC-Up™; FOXO3–AMPK–mTOR; HMGB1; bioelectrically enhanced exosomes. patents.google.com |
| Brain Health | Klotho Modulation — 11,471,686; 12,226,639; BDNF — 12,642,967; GDF10 — 12,611,540, as identified in company disclosures | Klotho-related pending platforms; CerebraCell™; Menin; glial-cell-mediated brain repair; HMGB1; FOXO3–AMPK–mTOR; OSER1; Sestrin application 2024/0285949. lionhearthealthstim.com |
| Immunity Health | Klotho Modulation — 11,471,686; 12,226,639; inflammation treatment — 11,110,274 | Klotho-related pending platforms; thymulin—provisional preparation announced; FOXO3–AMPK–mTOR; 15-PGDH; bioelectrically enhanced exosomes. patents.google.com |
| Vision Health | Klotho Modulation — 11,471,686; 12,226,639; broad regeneration platform — 12,109,410; 10,646,644 | Klotho-related pending platforms, particularly Super PRF + Klotho-expressing cells, whose announcement expressly includes vision; FOXO3–AMPK–mTOR platform identifies EyeCell™ among planned applications. patents.google.com |
| Hearing Health | Klotho Modulation — 11,471,686; 12,226,639; broad regeneration platform — 12,109,410; 10,646,644 | Super PRF + Klotho-expressing cells expressly includes hearing; Wnt activation/control proposes cochlear hair-cell regeneration; broader Klotho cellular platforms remain proposed applications. patents.google.com |
| Skin Regeneration | Klotho Modulation — 11,471,686; 12,226,639; Skin Treatment System — 11,819,688; COL17A1 Modulation — 11,878,161 | Klotho-related pending platforms; HMGB1; bioelectrically enhanced exosomes; enhanced peptide uptake; FOXO3–AMPK–mTOR. patents.google.com |
| Hair Regeneration / Repigmentation | Klotho Modulation — 11,471,686; 12,226,639; COL17A1 — 11,878,161; Bioelectric Stimulator — 12,109,410 | Klotho-related pending platforms; hair repigmentation provisional, expressly incorporating Klotho nanoflowers and Klotho-expressing cells in hydrogel; Wnt; HMGB1; enhanced exosomes and peptide uptake. patents.google.com |
| Oral Health | Klotho Modulation — 11,471,686; 12,226,639; Orthodontic Treatment — 10,695,563, subject to OrthodontiCell/Lionheart field-rights confirmation | DentaCell™ provisional platform, including Klotho signaling and regenerative biologics; ArchStim™ expansion/stabilization provisional; broader Klotho biologic combinations require oral-field confirmation. patents.google.com |
| Breathing / Airway Health | Schuler respiratory control — 6,937,903; Klotho Modulation — 11,471,686; 12,226,639, relevant to the lung-support platform | ArchStim™ airway/arch-expansion application; RegenaLung™ Klotho-expressing stem-cell inhaler. These address different airway and lung functions. patents.google.com |
| Lung Regeneration | Klotho Modulation — 11,471,686; 12,226,639; broad organ-regeneration platform — 10,646,644; 12,109,410 | RegenaLung™ provisional; Klotho-related pending platforms, including Super PRF/cell combinations expressly mentioning lungs and the Octopus multi-organ platform. patents.google.com |
| Heart Regeneration | Klotho Modulation — 11,471,686; 12,226,639; 10,646,644; 12,109,410 | Klotho-related pending platforms; HMGB1; bioelectrically enhanced exosomes; FOXO3–AMPK–mTOR. BioLeonhardt/Lionheart licensed fields require reconciliation. patents.google.com |
| Liver Regeneration | Klotho Modulation — 11,471,686; 12,226,639; broad organ-regeneration platform — 10,646,644; 12,109,410 | Klotho-related pending platforms, particularly Super PRF/cell combinations, Octopus and prepared KlothoPatch II. LiverCell macrophage therapy is a research program; a separate filing was not established. patents.google.com |
| Kidney Regeneration | Klotho Modulation — 11,471,686; 12,226,639; Kidney Treatment — 11,446,488 | Klotho-related pending platforms; FOXO3–AMPK–mTOR kidney-support applications; regenerative biologic combinations. patents.google.com |
| Pancreas Regeneration | Klotho Modulation — 11,471,686; 12,226,639; 10,646,644; Schuler gland regulation — 7,058,446; 9,254,388 | Klotho-related pending platforms, particularly Super PRF/cell combinations, Octopus and prepared KlothoPatch II/PancreaCell-related embodiments. patents.google.com |
| Diabetes / Metabolic Health | Klotho Modulation — 11,471,686; 12,226,639; Schuler endocrine regulation — 7,058,446; 9,254,388 | Klotho-related pending platforms as proposed metabolic/pancreatic applications; FOXO3–AMPK–mTOR; osteocalcin; MitoCell/PC-Up. Dedicated diabetes claim scope remains to be verified. patents.google.com |
| Blood Pressure Modulation | Klotho Modulation — 11,471,686; 12,226,639; Bioelectric Blood Pressure Management — 11,167,141; Schuler — 6,957,106, per company portfolio summary | FOXO3–AMPK–mTOR expressly includes blood-pressure optimization; Klotho-related pending platforms provide proposed vascular/organ-support combinations, subject to claim and field review. patents.google.com |
| Wound Healing | Klotho Modulation — 11,471,686; 12,226,639; 10,646,644; 12,109,410 | Klotho-related pending platforms; HMGB1; thymulin preparation; enhanced exosomes; FOXO3–AMPK–mTOR; DentaCell for oral wounds. patents.google.com |
| Bone Density / Bone Regeneration | Klotho Modulation — 11,471,686; 12,226,639; broader regenerative platform — 12,109,410 | BMP9 application — 2022/0370791; osteocalcin provisional; FOXO3–AMPK–mTOR; Menin; DentaCell for oral bone. Klotho-cell/hydrogel combinations are broader proposed platforms. patents.google.com |
The same Klotho patents appear in multiple functional categories; they should be counted once in the patent inventory. Patent-pending platforms likewise need to be reconciled by application number before calculating a total number of filings.
Issued Leonhardt Patents
17 issued Leonhardt patents are supported by the inventor/assignee listings and individual patent records. Justia Patents Search
| Issued patent | Subject |
|---|---|
| US12642967 | BDNF modulation |
| US12611540 | GDF10 modulation |
| US12226639 | Klotho modulation |
| US12109410 | Bioelectric stimulator / follistatin |
| US11878161 | COL17A1 modulation |
| US11849910 | Heart-valve decalcification, regeneration and repair |
| US11819688 | Skin treatment |
| US11691007 | Bioelectric OPG cancer treatment |
| US11471686 | Klotho modulation |
| US11446488 | Kidney treatment |
| US11433231 | Sonic hedgehog expression |
| US11185691 | Tumor therapy |
| US11167141 | Blood-pressure management |
| US11110274 | Inflammation treatment |
| US11052247 | Skin treatment |
| US10960206 | Bioelectric stimulator / follistatin |
| US10646644 | Stimulator, pump and composition |
| Issued subtotal | 17 |
Published Leonhardt Applications
The nine separate published applications below are counted independently of their related granted patents. SIRT remains in the application category in the records retrieved. Justia Patents Search
| Publication | Subject |
|---|---|
| US20260183342 | Allogenic implants for inflammatory conditions |
| US20240285949 | Sestrin modulation |
| US20240158813 | NANOG modulation |
| US20240108886 | SIRT modulation |
| US20230347144 | OPG cancer treatment continuation |
| US20230293268 | Bone integration / implant healing |
| US20220226643 | S100 modulation |
| US20220023623 | Sonic hedgehog delivery |
| US20200000709 | Bioelectric stimulation combined with platelet-rich fibrin |
| Published-application subtotal | 9 |
Additional News-Announced Applications
Additional 24 news-announced new applications prepared in 2026, which are in early filing processes of provisional or actual patent filings in steps.
| # | Application subject | Publicly described status |
|---|---|---|
| 1 | Nrf2 / aneurysm prevention | Provisional filed. lionheartlongevity.com |
| 2 | 15-PGDH / osteoarthritis and inflammation | Provisional filed. Lionheart Longevity |
| 3 | RegenaLung / Klotho-expressing cell inhaler | Provisional filed. Lionheart Longevity |
| 4 | FOXO3–AMPK–mTOR modulation | Provisional announced / in process. Lionheart Longevity |
| 5 | HMGB1 expression | Provisional announced. Lionheart Longevity |
| 6 | Wnt signaling | Provisional announced. Lionheart Longevity |
| 7 | Menin brain expression | Provisional filed. Lionheart Longevity |
| 8 | Osteocalcin expression | Provisional announced. Lionheart Longevity |
| 9 | OSER1 expression | Prepared—included. Lionheart Longevity |
| 10 | CerebraCell multi-protein brain regeneration | Completed application; subsequently described as filed. lionheartlongevity.com |
| 11 | Thymulin expression | Prepared—included. Lionheart Longevity |
| 12 | Polylaminin / spinal-cord regeneration | Provisional filed. Lionheart Health Stim |
| 13 | OrthoStim / PDA+ combination therapy | Provisional filed. Lionheart Longevity |
| 14 | Hair repigmentation | Provisional filed. lionheartlongevity.com |
| 15 | MitoCell / PC-Up mitochondrial restoration | Provisional filed. lionheartlongevity.com |
| 16 | Bioelectrically enhanced exosomes | Provisional filed. lionheartlongevity.com |
| 17 | Mitochondrial function, muscle strength and sarcopenia | Filing announced. lionheartlongevity.com |
| 18 | Glial-cell-mediated brain repair | Provisional filed. lionheartlongevity.com |
| 19 | KlothoPatch II organ bioreactor | Prepared—included. lionheartlongevity.com |
| 20 | Bioelectric enhancement of peptide uptake | Provisional filed. Lionheart Health Stim |
| 21 | Bioelectric-enhanced Klotho Nanoflowers | Nonprovisional filing announced. Lionheart Health Stim |
| 22 | Super PRF + Klotho-expressing stem cells | Provisional filing announced February 2025; subsequent status unverified. Leonhardt Ventures |
| 23 | DentaCell personalized regenerative dentistry | Provisional filed. lionheartlongevity.com |
| 24 | Lionheart Octopus multi-organ platform | Separately described as a recent provisional filing. lionheartlongevity.com |
| Additional announced-application subtotal | 24 |
TOTAL: Leonhardt licensed to Lionheart Health issued + published applications + announced applications, including prepared — 50
Schuler Patents Licensed or Optioned
I identified 11 issued U.S. patents naming Eleanor Schuler or Eleanor L. Schuler that public records currently report as active: eight cancer patents, one skeletal-muscle patent, and two broader neurocode-treatment patents.
| # | U.S. patent | Patent title / invention | Main application | Leonhardt / Lionheart relationship | Publicly reported status |
|---|---|---|---|---|---|
| 1 | 8,315,712 B2 | Hybrid scientific computer system for processing cancer cell signals as medical therapy | Recording, processing and modifying tumor signals for treatment | Licensed CancerCell portfolio | Active. Google Patents |
| 2 | 8,831,738 B2 | System and method to elicit apoptosis in malignant tumor cells for medical treatment | Modified electrical signals intended to trigger tumor-cell death | Licensed CancerCell portfolio | Active. Google Patents |
| 3 | 9,032,964 B2 | Method and system for processing cancer cell electrical signals for medical therapy | Recording tumor signals and generating confounding treatment signals | Licensed CancerCell portfolio | Active. Google Patents |
| 4 | 9,295,835 B2 | Encoded bioelectronic method and system and calcium treatment for slaying cancer by rapid triggering of cellular apoptosis and karyorrhexis | Encoded signals and calcium-based tumor-cell destruction | Licensed CancerCell portfolio | Active. Google Patents |
| 5 | 9,440,083 B2 | Rapid destruction of malignant tumors by excitotoxicity and osmotic-shock medical tactics | Tumor-cell destruction through excitotoxicity and osmotic shock | Licensed CancerCell portfolio | Active. Google Patents |
| 6 | 9,492,478 B2 | Encoded bioelectronic method and system and calcium treatment for slaying cancer by rapid triggering of cellular apoptosis and karyorrhexis | Additional claims concerning encoded signals, calcium and tumor-cell destruction | Licensed CancerCell portfolio | Active. Google Patents |
| 7 | 9,636,507 B2 | Rapid destruction of malignant tumors by excitotoxicity and osmotic-shock medical tactics | Additional tumor-treatment claims within the related portfolio | Licensed CancerCell portfolio | Active. Google Patents |
| 8 | 9,707,403 B2 | Rapid destruction of malignant tumors by excitotoxicity and osmotic-shock medical tactics | Additional claims concerning tumor-cell destruction | Licensed CancerCell portfolio | Active. Google Patents |
| 9 | 8,781,593 B2 | System and method for controlling skeletal muscles by means of neuro-electrical coded signals | Controlling skeletal-muscle activation and movement using recorded neurocodes | Option rights per your clarification; specific exercised muscle license not independently matched | Active. Google Patents |
| 10 | 11,154,238 B2 | Systems, methods and apparatuses for providing bioelectronic neurocode-based therapies to mammals | Monitoring physiological conditions and delivering responsive neurocode treatment, including cancer applications | Option rights per your clarification | Active — Reinstated. Google Patents |
| 11 | 11,950,923 B2 | Systems, methods and apparatuses for providing bioelectronic neurocode-based therapies to mammals | Related monitoring, communication and responsive treatment systems | Option rights per your clarification | Active. Google Patents |
| TOTAL | 11 issued U.S. patents identified as reported active | 8 cancer + 1 skeletal muscle + 2 broader neurocode systems | 8 publicly identified cancer licenses; remaining rights as described above | Enforceability not independently certified | |
Manfred Stangl License Patents — Exclusive in Combination with Bioelectric Stimulation Worldwide
The Manfred Stangl Klotho-cell technology is one patent family titled “Genetically modified mesenchymal stem cell expressing Klotho,” co-invented with Christine Günther and Felix Hermann. It now includes an issued U.S. patent granted February 24, 2026. Google Patents
| Patent / publication | Territory | Status | Relationship to the licensed Klotho-cell technology |
|---|---|---|---|
| US 12,559,724 B2 | United States | Issued February 24, 2026; reported active | U.S. grant within the Stangl/Günther/Hermann family. Covers genetically modified Klotho-expressing MSC technology; license coverage of this subsequent grant requires the agreement’s patent schedule. Google Patents |
| EP 3,262,159 B1 | Europe | Issued July 24, 2019; reported active | European grant for the same invention. Enforceable territories depend on national validations and renewal payments. Google Patents |
| WO 2016/135295 A1 | International PCT | Published September 1, 2016; PCT phase ceased | Original international publication identifying the technology; it is not a separate issued worldwide patent. Google Patents |
| US 2022/0033779 A1 | United States | Published February 3, 2022; subsequently granted | Application publication that became US 12,559,724 B2; count it together with that grant. Google Patents |
| US 2018/0037868 A1 | United States | Earlier application; reported abandoned | Earlier U.S. family member; excluded from issued-patent count. Google Patents |
| COUNT | 1 patent family; 2 identified issued grants—1 U.S. and 1 European | Applications and European national validations are not counted as additional independent inventions. |
The central invention uses mesenchymal stem cells genetically engineered with a Klotho-encoding sequence so the cells produce Klotho. Its disclosure includes proposed applications in kidney disease, fibrosis, cancer, neurodegenerative disease, diabetes, cardiovascular disease and other age-related conditions. Google Patents
SIRT6 Patent Now Issued
The SIRT6 patent is now issued. U.S. Patent No. 12,752,107, “Modulation of SIRTIUNS for Healthspan Longevity and Organ Regeneration,” is scheduled to be published as issued October 6, 2026.
Summary
These patent claims cover technologies designed to read the body’s electrical signals and deliver carefully programmed signals that influence how cells, nerves and organs work—including encouraging the body to produce proteins involved in healing, muscle strength, brain health and healthy aging. They also cover approaches that combine electrical stimulation with Klotho-producing stem cells, peptides, exosomes, nutrient gels and controlled-delivery devices to support tissue repair. Applications span skin and hair regeneration, joint and bone healing, dental-implant recovery, blood-pressure control and regeneration of organs such as the heart, kidneys, lungs and brain, alongside methods intended to disrupt cancer-cell communication and promote cancer-cell death. The portfolio includes issued claims, proposed claims in pending applications and estimated claims for prepared applications; patent coverage itself does not establish that a treatment works.
Patents and technologies in combination lead to development of a whole body regeneration chamber with multi-organ regeneration capability — a “womb for adults.”
Important Disclaimers: Issued patents may be invalidated with prior art references. Patents pending may not be issued or claims may be reduced in scope. Patents in process may not complete the filing process and may be rejected by the USPTO. Licensed and optioned patents are subject to multiple conditions to remain licensed which may not be met. If maintenance fees are not paid on time, some patents may lapse in enforceability. Some provisional patents may not be converted to full patent applications due to funding budget constraints or other reasons.